Article · 28 Aug 2023
Short communicationPublished 29 Sep 2020
A case of Haemophagocytic Lymphohistocytes (HLH) and presumed COVID 19
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: It is known that COVID-19 can cause an intense cytokine mediated immune response leading to various complications such as acute respiratory distress syndrome. However, one extreme of such a strong immune response is Haemophagocytic Lymphohistocytosis (HLH). It is emerging that COVID-19 can also lead to secondary HLH. Case presentation: A 20-year-old male with no previous medical history presented with a week’s history of abdominal pain, fever, diarrhoea and vomiting. Lactate was raised at 4 so a CT abdomen-pelvis was arranged which revealed hepatosplenomegaly, ascites and bilateral axillary lymphadenopathy. Ferritin was raised at 8645 on presentation but rose to >40,000 at the peak, LDH were 491, ESR 2 and CRP 90. A diagnosis of HLH was suspected and confi rmed after a bone marrow aspirate which revealed haemophagocytosis of neutrophils and erythroid cells. The rest of the autoimmune, vasculitic and viral screen was negative however underlying infection was suspected due to raised CRP. COVID-19 antigen swabs were done twice, but both came back as negative however clinically the virus was highly suspected. He received etoposide for treatment of HLH but the patient developed an acute oxygen requirement and bilateral pulmonary infi ltration that was highly suspicious of COVID-19. The patient acutely deteriorated and unfortunately died. Discussion: Secondary HLH has also been found in patients with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). It is likely that it develops in patients in COVID-19 too as all three viruses trigger a similar cytokine mediated storm. It is probably present in more patients than we know with COVID-19 and likely to contribute to prognosis and mortality. Conclusions: Recognising HLH is a potential complication of COVID-19 especially in those who are young with the ability to mount a strong immune response at an early stage could affect outcome by initiating early treatment.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutical Toxicology.
Mini review · 28 Aug 2023
Pharmaceuticals have Contributed Greatly to Medical Advancements and Improved Public Health
Article · 28 Aug 2023
Pharmaceutical Revolution Lies in the Field of Vaccine Development
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Toxicology
- SubjectPharmaceutical Sciences
- SubjectToxicology
- BylineArticles whose byline prints “Swetha Byravan”